SEC Form 4 · accession 0001209191-18-057432

Twist Bioscience Corp · TWST

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Nov 2, 2018

Accepted (ET)

Nov 6, 2018 · 5:01 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001581280

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Nov 2, 2018	C	542,203	—	A	542,203	I	By Illumina, Inc.
Common Stock^F1,F2	Nov 2, 2018	C	329,305	—	A	871,508	I	By Illumina, Inc.
Common Stock^F1,F2	Nov 2, 2018	C	673,378	—	A	1,544,886	I	By Illumina, Inc.
Common Stock^F1,F2	Nov 2, 2018	C	157,215	—	A	1,702,101	I	By Illumina, Inc.
Common Stock	holding	—	—		—	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F2,F1	—	Nov 2, 2018	C	542,203	D	—	—	Common Stock	542,203	I
Series B Preferred Stock^F2,F1	—	Nov 2, 2018	C	329,305	D	—	—	Common Stock	329,305	I
Series C Preferred Stock^F2,F1	—	Nov 2, 2018	C	673,378	D	—	—	Common Stock	673,378	I
Series D Preferred Stock^F2,F1	—	Nov 2, 2018	C	157,215	D	—	—	Common Stock	157,215	I

F1The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.
F2The Reporting Person is the Senior Vice President, Global Quality and Operations of Illumina, Inc. and has sole voting and dispositive power over the shares held of record by Illumina, Inc. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.